RESPECT: Drainless Robot-assisted Minimally Invasive Esophagectomy

Sponsor
Technische Universität Dresden (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05553795
Collaborator
German Cancer Research Center (Other)
72
1
2
26
2.8

Study Details

Study Description

Brief Summary

The aim of this study is the evaluation of two different chest drain management strategies in patients undergoing robot-assisted minimally invasive esophagectomy (RAMIE) for esophageal cancer with regard to perioperative complications until discharge.The primary objective of the study is to investigate whether the intensity of postoperative pain can be significantly reduced by avoiding thoracic drains after RAMIE. We assume that this will influence secondary endpoints such as early recovery and length of hospital stay.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Early removal of chest drain
  • Procedure: Chest drain
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
72 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized controlled multicentric trialRandomized controlled multicentric trial
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Drainless Robot-assisted Minimally Invasive Esophagectomy
Anticipated Study Start Date :
Oct 1, 2022
Anticipated Primary Completion Date :
Oct 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: A - Early removal of chest drain

Procedure: Early removal of chest drain
Chest drains are removed 3 hours after the end of surgery in absence of contraindications in arm A.

Other: B - Control

Procedure: Chest drain
The chest drains in arm B are removed during the further postoperative course according to standard algorithm.

Outcome Measures

Primary Outcome Measures

  1. Postoperative pain [Day 2 after surgery]

    Postoperative pain according to a numeric rating scale

Secondary Outcome Measures

  1. Mean postoperative pain [Day 4 after surgery]

    Postoperative pain according to a numeric rating scale

  2. Additional analgesic drug use [Day 4 after surgery]

    opioids [mg], non-opioids [mg]

  3. Postoperative mobilization [Day 7 after surgery]

    steps per day as measured with an activity tracker

  4. Postoperative morbidity [Through hospital stay, an average of 14 days]

    The postoperative morbidity of all patients is assessed with the comprehensive complication index based on Clavien Dindo classification from postoperative day 1 until day of discharge

  5. Postoperative mortality [Through hospital stay, an average of 14 days]

    The postoperative mortality of all patients is assessed between operation date and date of death of any cause during hospital stay

  6. Daily postoperative pain [Day 7 after surgery]

    Postoperative pain according to a numeric rating scale measured daily from postoperative day 1-7

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients scheduled for elective RAMIE for esophageal cancer with intrathoracic esophagogastrostomy (Ivor-Lewis)

  • American Society of Anesthesiologists (ASA) score ≤ III

  • Eastern Cooperative of Oncology Group (ECOG) status ≤ II

  • Patient suitable for both surgical techniques

  • Ability of subject to understand character and individual consequences of the clinical trial

  • Written informed consent

Exclusion Criteria:
  • Open esophagectomy (either abdominal or during the thoracic part)

  • Emergency operations

  • ASA IV

  • ECOG > II

  • Chronic pain syndromes requiring routine analgesics

  • Simultaneous lung resection

  • Presence of contraindications to the use of epidural anesthesia (e.g. coagulopathies, anticoagulation or allergies)

  • Participation in an interventional trial, which interferes with the outcome

  • Impaired mental state

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Gastrointestinal-, Thoracic and Vascular Surgery University Hospital Carl Gustav Carus Technische Universität Dresden Dresden Saxony Germany 01307

Sponsors and Collaborators

  • Technische Universität Dresden
  • German Cancer Research Center

Investigators

  • Principal Investigator: Johanna Kirchberg, Dr. med., Department of Gastrointestinal-, Thoracic and Vascular Surgery University Hospital Carl Gustav Carus

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Technische Universität Dresden
ClinicalTrials.gov Identifier:
NCT05553795
Other Study ID Numbers:
  • VTG-11
First Posted:
Sep 23, 2022
Last Update Posted:
Sep 23, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Technische Universität Dresden

Study Results

No Results Posted as of Sep 23, 2022